Medical 222-nanometer far ultraviolet blood therapy instrument
Through the medical 222 nanometer far-ultraviolet hemotherapy device, the 222 nanometer ultraviolet ray and heating treatment, interrupt the genetic chains of viruses and bacteria, and form a "live vaccine" to stimulate autoimmune response, solving the vaccine development and vaccination process time in the existing technology. The problem of excessive long has achieved rapid disinfection and immune memory of new coronavirus and broad-spectrum pathogens, and improved patients' rehabilitation ability.
Patent Information
- Application Number
- CN202410526306.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-04-29
- Publication Date
- 2024-11-26
AI Technical Summary
The existing technology cannot quickly and in real time to produce and on-site vaccination for individual patients, resulting in the long time of vaccine development and vaccination process, and it is impossible to effectively deal with rapidly mutated lethal virus and bacterial infections.
Using a medical 222-nanometer far-ultraviolet hemotherapy device, 222-nanometer ultraviolet rays interrupt the RNA/DNA genetic chains of viruses and bacteria, inactivate them, and deactivate the blood through the heating chamber to form a "live vaccine" to stimulate autologous Immune response, simplifying vaccine production and vaccination processes.
It has achieved rapid disinfection and immune memory of new coronavirus and broad-spectrum pathogens, reduced the vaccine production and vaccination process, saved time, avoided the dangers caused by high temperature fever, and improved patients' rapid recovery ability.
Smart Images

Figure CN119015530A_ABST
Abstract
Description
[0001] The present invention relates to medical technology, public health, precision medicine, external treatment of internal diseases, immunotherapy, physics and life sciences, and in particular to a medical 222-nanometer far-ultraviolet blood therapy device. Background Art
[0002] The human immune system is the best medicine. Medicine is poisonous. Physical therapy may be the best medical solution. In 1796, Edward Jenner of England invented the cowpox vaccine, which was the first successful vaccine in human history and made an immortal contribution to human victory over the smallpox virus. As of January 1, 2024, 228 years have passed.
[0003] In 1885, Frenchman Louis Pasteur invented the first rabies vaccine for humans using the method of multiple attenuation and inactivation. In 1904, humans discovered that ultraviolet rays could be used for disinfection. Dr. Heraeus of Germany invented the ultraviolet lamp (which cannot be used for disinfection by humans and machines at the same time), which marked the beginning of the first year of medical light disinfection for humans. As of January 1, 2024, 120 years have passed.
[0004] In 1928, Alexander Fleming, a British biochemist, microbiologist, and bacteriologist, discovered penicillin. This opened the door to the birth of the antibiotic family, ushering in a new era of antibiotic treatment of diseases. It also gave birth to a drug that had long been unable to effectively treat bacterial infections with minimal side effects in human medical history, greatly extending the average human lifespan by 20 years. As of January 1, 2024, 96 years have passed.
[0005] On October 2, 2023, Hungarian Katalin Kolik and American Drew Weissman won the 2023 Nobel Prize in Physiology or Medicine in recognition of their breakthrough discoveries in messenger RNA (mRNA) research, which helped to accelerate vaccine development at an unprecedented speed. As of January 1, 2024, only 28 days have passed.
[0006] The essence of human illness is the imbalance of biological safety in the patient's body. All medicines are toxic. The medical 222-nanometer far-ultraviolet blood therapy device is a pure physical medical technology that does not require medication during treatment.
[0007] Opening: As a new technology, immunology is booming. However, the world's most deadly drug-resistant fungal infections (Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, Neisseria gonorrhoeae, Staphylococcus aureus, Escherichia coli, Mycobacterium tuberculosis), immune escape diseases (HIV, COVID-2019, cancer, mycoplasma infection, etc.) have always been medical problems.
[0008] Currently, there are no medical instruments or equipment in the world that can prepare and administer vaccines to individual patients in real time. Summary of the invention
[0009] To achieve the above-mentioned purpose, the present invention provides a medical 222-nanometer far-ultraviolet blood therapy instrument, including: 1. a heating chamber, 2. a 222-nanometer ultraviolet disinfection chamber, 3. a lamp holder, 4. a lamp tube, 5. a reflector, 6. a heater layer, 7. a display control panel, 8. a charging port, 9. a removable and replaceable battery, 10. a chamber cover buckle, 11. a filter, 12. a card slot, 13. a needle cap, 14. an injection needle 1, 15. a push needle wing, 16. a drip pot, 17. a dosing device, 18. a light disinfection tube, 19. a current limiter, 20. an injection needle 2, 21. a needle cap 2, 22. a rectifier, 23. a reflector, 24. a switch, a total of 24 parts. The present invention further provides that the medical 222 nanometer far ultraviolet blood therapy device has the following advantages: The present invention shortens the manufacturing time of the vaccine and eliminates the need for storage, constant temperature transportation, scheduled injection and vaccination, and the like.
[0010] Currently: The fastest development time for humans to develop vaccines for infectious diseases with relatively stable antigens is 4.5 years (Merck's mumps vaccine), and the average development time for a vaccine is 8-15 years.
[0011] For HIV or COVID-2019 that escapes immunity, At present, it takes the following steps and time for humans to produce vaccines. (1) Collection of corpses of people who died of the same disease (elderly, young, children, men, women) (2) Collection of a certain number of representative animal carcasses (species that can be transmitted between humans and animals) (3) Autopsies of a certain number of bodies: to identify organs where inflammation is concentrated or the cause of death, and to begin sampling for pathogens.
[0012] (4) Screening for pathogenic pathogens to identify or confirm the lethal pathogen (requires a cryo-electron microscope with a magnification of more than 1 million times) and takes about 3 months.
[0013] (5) Amplification of pathogenic pathogens.
[0014] (6) Inactivation or attenuation of pathogenic pathogens (temperature method, pressure method, chicken embryo method, MDCK (canine kidney cell) method, recombinant protein method, mRNA method).
[0015] (7) Vaccines are tested on animals.
[0016] (8) The vaccine will undergo Phase III human trials.
[0017] (9) Approved by the expert panel and approved by the government for production and use.
[0018] (10) Mass production, constant temperature storage, and constant temperature transportation.
[0019] (11) Make an appointment for vaccination.
[0020] At least 11 steps need to be completed. The first 6 steps will take at least 3 months to complete, and the last 5 steps will take at least 6 months. The sick bats have been running a fever, and the virus has been evolving. The virus usually replicates once in 6-8 hours, and the iteration is completed in one month. Many people have paid the price of their lives because of the long time it takes to develop vaccines and promote their use. The current 6 methods of vaccine manufacturing in humans are (1) temperature method, (2) pressure method, (3) chicken embryo method, (4) MDCK (canine kidney cell) method, (5) recombinant protein method, and (6) mRNA method. If the vaccine cannot be completed and vaccinated within 6-8 hours, the current vaccine manufacturing, vaccination, prevention, and patient treatment will be lost to time and the virus. The medical 222-nanometer far-ultraviolet blood therapy device uses 222-nanometer ultraviolet rays that cannot penetrate the stratum corneum of human skin and the cornea of human eyes, but can interrupt the RNA\DNA genetic chain of viruses, bacteria and pathogens, making the viruses inactive and unable to replicate, achieving the purpose of human-machine coexistence disinfection. At the same time, the envelope protein or spike protein of the viruses, bacteria and pathogens whose RNA\DNA genetic chains are interrupted does not change, which is equivalent to making a "live vaccine". These "live vaccines" are re-introduced into the human body through the blood, causing the human body's immune response and reaction. After the viruses, bacteria and pathogens whose RNA\DNA genetic chains are interrupted enter the human body, they stimulate the lymphocytes in the human body to produce humoral immunity and cellular immunity. Due to the small number of pathogenic pathogens entering the human body, the DNA\RNA genetic chain is interrupted and cannot be replicated, and there is no "reinforcement". Relying on its huge immune system, the human body quickly and easily ends the immune "battle" and protects the safety of the human body. However, such a "battle" will form immune memory. When the same pathogenic pathogens invade the human body in the future, the human body will quickly mobilize the immune system to defeat the invader. Protect human health.
[0021] Under the irradiation of 222-nanometer ultraviolet rays, the virus can be disinfected within 10 seconds. The 222-nanometer ultraviolet disinfection equipment designed and produced by the invention team has been tested by the Chinese Academy of Sciences (China Science Testing Co., Ltd.) and has a 10-second killing rate of 99.98%-99.99% for coronavirus and 99.94%-99.98% for influenza A H1N1.
[0022] Similarly, the present invention uses a heating chamber to heat the blood to 41-47°C, or even 50°C (below the limit temperature of protein mutation), so as to inactivate bacteria and viruses. Such inactivated bacteria and viruses, when transfused back into the patient, will induce an autoimmune response, allowing the patient to exert the function of the autoimmune system and defeat the invading bacteria and viruses.
[0023] The medical 222-nanometer far-ultraviolet blood therapy device of the present invention can inactivate or disinfect the new coronavirus and a wide spectrum of pathogenic pathogens (millions of types). It can also reduce many links in vaccine production and vaccination through autologous extracorporeal blood transfusion and natural immunization, saving a lot of time in the race against viruses, bacteria, and pathogenic pathogens.
[0024] The present invention can select a single heating mode and a 222-nanometer ultraviolet irradiation mode and a common mode to sterilize the patient's own blood and prepare and vaccinate the patient in real time and on-site, and has a simple structure.
[0025] The present invention uses a purely physical method to treat patients, and utilizes the opportunity of extracorporeal blood circulation to heat up and disinfect with 222 nanometer ultraviolet light to avoid the high temperature fever and fever in the patient's body, and the dangers of water and electrolyte disorders, pneumonia, organ hydrops, multiple organ failure, nerve spasm, etc. caused by the high temperature fever and fever in the patient's body. The limit of high fever in the human body is 41°C. If it exceeds 41°C, it is very dangerous. However, by heating the blood to between 41-47°C during the period of extracorporeal blood circulation, bacteria, viruses, and drug-resistant fungi can be killed, and the patient will not experience the pain and danger of high fever and high fever. In this temperature range, the plasma of the autologous blood transfusion will not have a negative impact. At the same time, the bacteria, viruses, and cancer cells that are killed by heating return to the patient's body. Because the membrane protein or the spike protein has not changed, the inactivated bacteria or viruses will stimulate the autoimmune response. The human body, relying on a strong immune system, begins to identify immune escape viruses and cancer cells, and forms immune memory. A "counterattack" can be launched to defeat the bacteria and viruses that invade the human body and make the patient recover.
[0026] The present invention uses a purely physical 222-nanometer ultraviolet irradiation method to disinfect the extracorporeal blood. The 222-nanometer ultraviolet wave interrupts the RNA or DNA chain of viruses and bacteria, making the viruses or viruses unable to replicate. However, the membrane protein and spike protein of the bacteria and viruses that are extinguished do not change. After being transfused back into the patient's body, it will stimulate the patient's autoimmune memory and immune response. The human body relies on the immune system to defeat the invading viruses and bacteria with the majority and the fast against the slow. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 It is a schematic diagram of the structure of an embodiment of the present invention; Including: 1. Heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. Lamp head, 4. Lamp tube, 5. Reflector, 6. Heater layer, 7. Display control panel, 8. Charging port, 9. Removable and replaceable battery, 10. Chamber cover buckle, 11. Filter, 12. Card slot, 13. Needle cap, 14. Injection needle 1, 15. Push needle wing, 16. Drip pot, 17. Dosing device, 18. Light disinfection tube, 19. Current limiter, 20. Injection needle 2, 21. Needle cap 2, 22. Rectifier, 23. Reflector, 24. Switch, a total of 24 parts. DETAILED DESCRIPTION
[0028] Preferred embodiment 1, please refer to Figure 1 As shown, it includes: 1. Heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. Lamp head, 4. Lamp tube, 5. Reflector, 6. Heater layer, 7. Display control panel, 8. Charging port, 9. Removable and replaceable battery, 10. Chamber cover buckle, 11. Filter, 12. Card slot, 13. Needle cap, 14. Injection needle 1, 15. Push needle wing, 16. Drip pot, 17. Dosing device, 18. Light disinfection tube, 19. Current limiter, 20. Injection needle 2, 21. Needle cap 2, 22. Rectifier, 23. Reflector, 24. Switch, a total of 24 parts. Medical 222 nanometer far ultraviolet blood therapy device Preferred embodiment 2, please refer to Figure 1 The medical 222 nanometer far ultraviolet blood therapy device shown includes: 1. Heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. Lamp head, 4. Lamp tube, 5. Reflector, 6. Heater layer, 7. Display control panel, 8. Charging port, 9. Removable battery, 10. Chamber cover buckle, 11. Filter, 12. Card slot, 13. Needle cap, 14. Injection needle 1, 15. Push needle wing, 16. Drip pot, 17. Doser, 18. Light disinfection tube, 19. Current limiter, 20. Injection needle 2, 21. Needle cap 2, 22. Rectifier, 23. Reflector, 24. Switch, 25. Oxygenation module, a total of 25 parts. 222 nanometer ultraviolet oxygenation blood therapy device.
[0029] Embodiment 3, the present invention provides a medical 222 nanometer far ultraviolet blood therapy instrument, including: 1. Heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. Lamp head, 4. Lamp tube, 5. Reflector, 6. Heater layer, 7. Display control panel, 8. Charging port, 9. Removable battery, 10. Chamber cover buckle, 11. Filter, 12. Card slot, 13. Needle cap, 14. Injection needle 1, 15. Push needle wing, 16. Drip pot, 17. Dosing device, 18. Light disinfection tube, 19. Current limiter, 20. Injection needle 2, 21. Needle cap 2, 22. Rectifier, 23. Reflector, 24. Switch, 25. Filter module, a total of 25 parts. 222 nanometer ultraviolet blood lipid blood therapy instrument.
[0030] Preferred embodiment 4, the present invention provides a medical 222 nanometer far ultraviolet blood therapy instrument, including: 1. heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. lamp head, 4. lamp tube, 5. reflector, 6. heater layer, 7. display control panel, 8. charging port, 9. removable battery, 10. chamber cover buckle, 11. filter, 12. card slot, 13. needle cap, 14. injection needle 1, 15. push needle wing, 16. drip pot, 17. doser, 18. light disinfection tube, 19. current limiter, 20. injection needle 2, 21. needle cap 2, 22. rectifier, 23. reflector, 24. switch, 25. oxygenation module, 26. filter module, a total of 26 parts. 222 nanometer ultraviolet blood lipid oxygenation therapy instrument.
[0031] So far, the above preferred technical solutions of the present invention have been described in conjunction with the preferred embodiments shown in the accompanying drawings. However, it is easy for those skilled in the art to understand that the protection scope of the present invention is obviously not limited to these specific preferred embodiments. Those skilled in the art should understand that they can still modify the technical solutions recorded in the previous preferred embodiments, or replace some or all of the technical features therein; and these modifications or replacements do not make the corresponding technical solutions deviate from the scope of the technical solutions of the present invention. The technical solutions after these changes or replacements will be included in the claims and description of the present invention, and are also covered within the scope of legal protection.
Claims
1. The present invention provides a medical 222 nanometer far ultraviolet blood therapy device, comprising: include:
1. Heating chamber, 2. 222 nanometer ultraviolet disinfection chamber, 3. Lamp holder, 4. Lamp tube, 5. Reflector, 6. Heater layer, 7. Display control panel, 8. Charging port, 9. Removable and replaceable battery, 10. Chamber cover buckle, 11. Filter, 12. Card slot, 13. Needle cap, 14. Injection needle 1, 15. Push needle wing, 16. Drip pot, 17. Dosing device, 18. Light disinfection tube, 19. Current limiter, 20. Injection needle 2, 21. Needle cap 2, 22. Rectifier, 23. Reflector, 24. Switch, a total of 24 parts.
2. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: Including but not limited to (1) treating internal diseases externally, using the process of autologous blood circulation to protect the effective components of plasma to produce vaccines for individual patients in real time, (2) producing vaccines by inactivating them by heating in vitro alone, (3) producing vaccines by inactivating them by irradiating them with 222nm ultraviolet light in vitro alone. (4) or producing vaccines by heating and 222nm ultraviolet light together.
3. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: The heating chamber includes, but is not limited to, ceramic heating, semiconductor heating, iron powder heating, graphene heating, etc.; the 222-nanometer far-ultraviolet light source includes, but is not limited to, a light source generated by high-frequency, high-voltage excimer technology or high-frequency, electromagnetic electrodeless technology, or LED technology. The light-transmitting part is coated with an optical filter film between 200 nanometers and 230 nanometers, which can filter stray light with a frequency below 200 nanometers and above 230 nanometers, and retain ultraviolet light with a peak of 222 nanometers at 200-230 nanometers.
4. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: Article 19 of the present invention: The current limiter includes but is not limited to: it can be manual or electronically controlled.
5. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: Including but not limited to: AC, DC, power supply, charging, portability, mobility, rechargeable and battery-replaceable, and no wiring required.
6. The medical 222 nanometer far-ultraviolet blood therapy device according to claim 1 is used in all hospitals and medical institutions, especially in the case of sudden large-scale natural disasters, wars, etc. where there are no drugs, or for the treatment of diseases such as antibiotic ineffectiveness, immune escape, cancer, etc.
7. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: In addition to human medical use, it can also be applied to animal treatment as a veterinary device.
8. The medical 222 nanometer far ultraviolet blood therapy device according to claim 1 is characterized in that: Including but not limited to: oxygenation module, blood lipid filtration, disinfection immunity, and other functional modules can be added.
